Characterization of the Sensitizing Potential of Chemicals by In Vitro Analysis of Dendritic Cell Activation and Skin Penetration  by Aeby, Pierre et al.
Characterization of the Sensitizing Potential of Chemicals by In
Vitro Analysis of Dendritic Cell Activation and Skin Penetration
Pierre Aeby, Christoph Wyss, Heinz Beck, Peter Griem,y Heike Scheffler,w and Carsten Goebelw
Cosmital SA, (Research company of Wella AG) Marly, Switzerland; wDepartment of product safety, Toxicology, Wella AG, Darmstadt, Germany; yClariant GmbH,
Toxicology, Sulzbach am Tannus, Germany
Development of in vitro models to identify sensitizing chemicals receives public interest since animal testing
should be avoided whenever possible. In this article we analyze two essential properties of sensitizing chemicals:
skin penetration and dendritic cell (DC) activation. Activation of immature DC derived from peripheral blood
monocytes was evaluated by ﬂow cytometric analysis of CD86 positive cells and quantitative measurement of
interleukin-1b and aquaporin P3 gene expression. The sensitizer 2,4,6-trinitrobenzenesulfonic acid induced a
concentration-dependent response for all parameters, whereas the irritant sodium lauryl sulfate did not. When two
related aromatic amines, p-toluylenediamine (PTD) and hydroxyethyl-p-phenylenediamine (HE-PPD) were tested,
both induced substantial DC activation indicating their potential sensitizing properties. These ﬁndings contrasted
with in vivo results: in murine local lymph node assays (LLNA) PTD, but not HE-PPD, was sensitizing using acetone/
aqua/olive oil as vehicle. Skin penetration measurement revealed that this was due to bioavailability differences. On
retesting HE-PPD in the LLNA using the penetration enhancer dimethylsulfoxide as vehicle, it induced a speciﬁc
response. We conclude that in vitro analysis of DC activation capability of the two selected chemicals demonstrates
that prediction of skin sensitization potential is possible provided that skin penetration data indicate sufﬁcient
bioavailability of the test compound.
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Allergic contact dermatitis (ACD) is a delayed-type hyper-
sensitivity reaction induced by small reactive chemicals
(haptens). In pharmaceutical and cosmetic industries it is
mandatory to identify chemicals that are potential ACD
inducers before they become part of a new product.
Currently, the sensitizing potential of chemicals is usually
identified on the basis of animal studies, such as the local
lymph node assay (LLNA). There is, however, an increasing
public concern regarding the use of animal testing for the
screening of new chemicals. The development of in vitro
models for predicting the sensitizing potential of new
chemicals is therefore receiving widespread interest.
In vitro sensitization tests are furthermore needed to
identify the relevant aspects of the complex interactions of a
chemical with the different compartments of the immune
system (Ryan et al, 2001): The chemical must penetrate the
skin and react with endogenous proteins. Some chemicals,
termed prohaptens, require activation through skin meta-
bolism in order to become haptens capable of binding to
skin proteins. Haptenated self-proteins are internalized and
processed by immature dendritic cells (DC). DC activation
occurs upon skin contact with immunogenic chemicals
and activated DC upregulate a set of cell surface markers
(e.g., CD83 or CD86), secrete various cytokines, such as
interleukin (IL)-1b, and downregulate proteins involved in
antigen uptake such as aquaporins. In parallel, activated DC
start to migrate from the epidermis into the draining lymph
node, complete maturation and present fragments of the
haptenated self-proteins to T helper cells, resulting in an
antigen-specific immune response (Lepoittevin et al, 1998;
Smith and Hotchkiss, 2001).
The early work of Enk and Katz (1992), who demon-
strated that topical exposure of mice to chemical allergens
induces a rapid and specific upregulation of IL-1b in skin
DC, initiated the work of many research groups who
attempted to correlate the sensitizing potential of a
chemical with its ability to activate in vitro generated DC
(see Ryan et al, 2001 or Kimber et al, 2001, for recent
reviews). One important step towards the development of
in vitro sensitization assays was the generation of dendritic-
like cells from human peripheral blood monocytes (Lenz
et al, 1993; Romani et al, 1994; Sallusto and Lanzavecchia,
1994). But due to the variability between human donors and
the modest increases (usually approximately 2–3-fold) in
IL-1b mRNA upregulation observed in vitro, these assays
did not represent a robust test system for measuring the
sensitizing potential of a given chemical (Reutter et al, 1997;
Pichowski et al, 2000; Kimber et al, 2001). The capability of
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chemicals to induce the activation of in vitro generated DC
was further evaluated through measurements of HLA-DR,
CD54, CD83, CD86 (Aiba et al, 1997; Degwert et al, 1997;
Rougier et al, 2000; Tuschl and Kovac, 2001; Hulette et al,
2002), the production of various cytokines or chemokines,
for example, TNF-a, IL-1a, IL-6, IL-8, IL-10, and IL-12 (Lore´
et al, 1998; Aiba et al, 1999), or the phosphorylation of
protein kinases and tyrosine (Arrighi et al, 2001; Becker
et al, 2003). Nevertheless, a reliable prediction of the sensitiz-
ing potential based on DC activation in vitro was not
achieved because the in vitro results did not reflect the
actual ability to induce contact hypersensitivity in vivo (Ryan
et al, 2001).
We assume that the lack of the skin barrier in vitro and
the difficulties in obtaining relevant DC activation data are
responsible for this discrepancy. Therefore, we propose to
integrate in vitro skin penetration analysis using pig skin, the
most suitable model of human skin (Simon and Maibach,
2000; Schmook et al, 2001), and to use pooled immature
DC obtained from different donors to reduce inter-individual
variability that limit the interpretation of DC activation data.
The suitability of this approach was tested with two
aromatic amines, a class of chemicals comprising several
known sensitizers (Malkowski et al, 1983). The in vitro
findings for the two compounds were compared with their
potential to induce sensitization in vivo as measured by the
LLNA in mice.
Results
Human monocytes differentiate into dendritic-like cells
in the presence of IL-4 and GM-CSF Human monocytes
obtained from peripheral blood and cultured in presence of
IL-4 and GM-CSF resulted in cells displaying markers
typical of DC phenotype (CD14, CD1aþ , HLA-DRþ , and
CD86þ , see Figs 1 and 2). After 4 d in culture, these cells
were considered as immature DC-like cells, expressing a
low amount of CD86, and were used for the in vitro
stimulation test.
Modulation of the CD86 bright cell population and IL-1b
or AQP3 gene expression by exposure to irritant or
sensitizer DC-like cells obtained from a pool of four donors
were exposed to 2.5 and 5 mg per mL SDS as a model
irritant or to 200 mg per mL TNBS as a model sensitizer. Due
to the high cytotoxicity of SDS, concentrations higher than
5 mg per mL could not be tested. Since the effect of TNBS
was obvious, we wanted to check that the chosen markers
were not modulated by cell stress (5 mg per mL of SDS is at
the limit of cytotoxicity) and therefore tested two different
concentrations of SDS. Deionized water, the solvent for
SDS and TNBS was used as negative control. The CD86
positive population can be subdivided into two distinct
subpopulations (see Fig 2). The maturation of the DC-like
Figure 1
Flow cytometry analysis during the generation of DC-like cells. (A)
Freshly isolated peripheral blood monocytes obtained from four
different donors were thawed at day 0, pooled and cultured in presence
of IL-4 and GM-CSF as described. The percentage of cells positive for
CD1a, HLA-DR and CD14 was measured on days 1–4. The mean and
the standard error of the mean of 10 independent preparations are
shown. (B–D) Cytometry analysis of the cells during a representative
experiment. Filled, gray histograms give the reactivity with the
appropriate isotype-matched control. Thin line: Analysis performed at
day 1; bold line: Analysis at day 4.
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cells was estimated by measuring the proportion of the
CD86 ‘‘bright’’ subpopulation in the population of CD86
positive cells. This way of expressing the data allowed a
better readability of the results than a mean intensity of
fluorescence measurement. This is presumably due to the
fact that not all cells respond to the test substance.
Additionally, the relative amount of IL-1b mRNA and the
relative amount of AQP3 mRNA, a gene which is expressed
in immature DC and downregulated during DC maturation
(de Baey and Lanzavecchia, 2000) were measured. Time
points were 1.5, 3, 6, 11, 24, and 30 h (see Fig 3). In
presence of TNBS, the percentage of the CD86 bright cells
was comparable or below the value obtained with the
control up to 11 h incubation time and then increased up to
approximately 200% of control at 30 h. On the other hand,
SDS did not induce relevant modification of the CD86 bright
population after 24 or 30 h (see Fig 3A). A similar effect was
observed on the modulation of IL-1b gene expression.
Incubation with TNBS for more than 6 h induced relevant
increases in IL-1b gene expression and reached a maximum
of approximately 800% of control after 30 h exposure.
Exposure to SDS induced a maximum of 170% of control
after 11 h and then went back to 80% of control after 30 h
(see Fig 3D). Analysis of AQP3 gene expression demon-
strated a pronounced decrease of AQP3 expression (down
to 25% of control at 30 h) in the cells exposed to TNBS.
SDS did not affect AQP3 gene expression at any of the
tested time points (see Fig 3E). Based on these results, the
accumulation of CD86 bright cells and the analysis of IL-1b
and AQP3 gene expression by real-time RT-PCR were
chosen as parameters for further in vitro sensitization
studies. Due to the high variability of the test system at
short exposure times, 30 h was chosen as the optimal time
point for discriminating irritants from sensitizers.
The pooling of cell preparations containing DC and T
cells may lead to an allogeneic mixed lymphocyte reaction
(MLR). Control experiments (data not shown) were thus
performed with DC obtained from four single donors and
with DC obtained from a pool of the same donors. Upon
exposure to SDS and TNBS, similar and specific DC
activation patterns were observed with cells from single or
pooled donors. Moreover, the amount of contaminating T
cells (flow cytometric measurement of the CD3 positive
population) decreased sharply (9%–18% at day 1 to o3%
at day 4) during the culture of DC obtained from the single
or pooled donors. The predominance of an MLR in our test
system can thus be excluded.
Comparison of the dose response effects of PTD, HE-
PPD, and TNBS on cultured DC-like cells DC-like cells
were exposed to water as a negative control, 57–454 mM
PTD, 48–2500 mM HE-PPD, and 85–850 mM TNBS. Higher
doses showed a strong response inhibition or could not be
analyzed because of cell toxicity as determined by Trypan
blue exclusion or flow cytometry measurement of FDA
incorporation (data not shown). IL-1b and AQP3 gene
expression and the proportion of CD86 bright cells were
measured after 30 h incubation (see Fig 4). PTD, HE-PPD,
and TNBS were able to induce relevant increases in the
CD86 bright cell population (see Fig 4A). The concentrations
required to induce comparable effects were four to eight
times higher for HE-PPD and for TNBS than for PTD. The
three test substances induced also significant increases in
IL-1b gene expression (see Fig 4B). Again, the concentra-
tions required for a similar induction of IL-1b gene
expression were five to eight times higher for HE-PPD than
for PTD. TNBS showed intermediate induction potency. The
relatively stronger effect of PTD compared with HE-PPD
was confirmed by the AQP3 measurements. Again, PTD
was four to six times more potent than HE-PPD in inducing
a decrease in AQP3 gene expression and TNBS had an
intermediate effect (see Fig 4C).
Induction of contact sensitization in the LLNA PTD was
able to induce a concentration-dependent increase in the
LLNA response in the vehicle AAOO. A concentration
increase of 10 mg per mL (from 5 to 15 mg per mL)
induced an increase in the stimulation index from 4.4 to
10.4. The highest tested concentration of 28 mg per mL
(limit of solubility in AAOO) induced a stimulation index of
19.4 (Fig 5). The EC3, that is, the concentration that induced
a stimulation index of 3 was derived by linear regression
Figure 2
Flow cytometric analysis of the CD86 marker during the generation
of DC-like cells. (A) The CD86 positive cell population can be
subdivided into two distinct sub-populations: M1 indicates the CD86
positive cell population (signal higher than the corresponding isotopic
control). M2 indicates the CD86 ‘‘bright’’ subpopulation. Data were
collected during a representative routine experiment. Filled gray
histogram gives the reactivity with the appropriate isotype-matched
control and the line shows the profile of a typical DC population at day
4. (B) The expression of CD86 was measured during the generation of
dendritic-like cells from day 1 to 4 of culture. The mean and standard
error of the mean of the values obtained during 10 independent
preparations are represented. Of these CD86 positive cells, 5%–40%
expressed a comparatively large amount of CD86 (CD86 bright).
1156 AEBY ET AL THE JOURNAL OF INVESTIGATIVE DERMATOLOGY
(r240.99). The EC3 of 0.31% indicated a moderate
sensitizing potency for PTD in the vehicle AAOO (according
to Basketter et al, 2000). In contrast, HE-PPD did not induce
a stimulation index above 3 in AAOO at concentrations
of up to 28 mg per mL (limit of solubility in AAOO), that is,
HE-PPD would not be regarded as a sensitizer under these
conditions.
When DMSO was used instead of AAOO as vehicle for
HE-PPD, a concentration-dependent increase in the LLNA
response was observed. A concentration increase from 5 to
Figure 3
Kinetic analysis of CD86 surface expression and IL-1b and AQP3 gene expression on DC-like cells exposed to TNBS or SDS. DC-like cells
were exposed to vehicle alone (’) or to 200 mg per mLTNBS (m), 2.5 mg per mL () or 5 mg per mL (4) SDS. (A) Flow cytometry analysis of the CD86
bright population. The mean and standard error of the mean are indicated for TNBS (n¼5 independent experiments), for SDS at 2.5 mg per mL
(n¼ 2) and SDS at 5 mg per mL (n¼ 3). (B, C) Cytometry analysis of the cells exposed to TNBS (B) or SDS (C) during a representative experiment.
Filled, gray histograms give the reactivity with the appropriate isotype-matched control. Thin line: vehicle treated cells; bold line: cells treated with
200 mg per mLTNBS (B) or 5 mg per mL SDS (C). (D) Real-time RT-PCR measurements of IL-1b gene expression. The mean and standard error of the
mean of the value obtained with TNBS (n¼6) and the two concentrations of SDS (n¼ 3) are indicated. (E) Corresponding results for AQP3 gene
expression.
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10 mg per mL increased the stimulation index from 2.7 to
4.5 (Fig 5). The respective EC3, calculated by linear
interpolation using these data points, was 0.58% (according
to Basketter et al, 2000). When the EC3 was derived by
linear regression from all data points (r240.99), a nearly
identical value of 0.62% was found. The maximum solubility
of HE-PPD in DMSO was 20 mg per mL, which caused a
stimulation index of 7. PTD could not be tested in this
vehicle because it is nearly insoluble in DMSO.
Vehicle-dependent penetration of PTD and HE-PPD An
amount of about 4% PTD of the applied dose was found
to penetrate through pig skin after topical exposure
for 30 min, when AAOO was used as vehicle (Fig 6). Under
Figure 4
Dose response effects of PTD, HE-PPD and TNBS on cultured DC-like cells. DC-like cells were exposed to vehicle alone, 57–454 mM PTD (),
48–2500 mM HE-PPD (&) and 85–850 mM TNBS (m) for 30 h. (A) Flow cytometry analysis of the CD86 bright population, expressed as the
percentage ratio of the negative control. The mean and standard error of the mean of n¼ 4 independent experiments are represented (or n¼ 2 for
TNBS). (B) Measurements of IL-1b gene expression. The mean and standard error of the mean of 4 (PTD and HE-PPD) or 2 (TNBS) independent
experiments are shown. (C) Corresponding results for AQP3 gene expression.
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the same conditions, the penetration of HE-PPD was
about 200-fold lower (Fig 6). The penetration rate of
HE-PPD could be increased 5-fold to 0.1%, when DMSO
was used as vehicle instead of AAOO (Fig 6). Lower
penetration rates were measured for PTD and HE-PPD
from commercial hair dye formulations (Table I). The
recovery of PTD and HE-PPD was greater than 97% from
AAOO or DMSO and between 85% and 97% from
formulations (Table I).
Discussion
The establishment of in vitro sensitization methods for the
screening of new industrial chemicals is of major impor-
tance for the reduction of animal testing and the main-
tenance of product safety. The aim of this study was to
develop a test system based on two essential properties
of a skin sensitizing chemical that can be quantitatively
determined in vitro, namely, skin penetration and DC
activation. We evaluated whether these parameters are
suitable to explain the different sensitizing potential of the
two related aromatic amines, PTD and HE-PPD that are
used as oxidative hair dye precursors. Despite their
structural similarity, only PTD is known to induce positive
patch test reactions in hairdressers (Uter et al, 2000). The
different sensitizing potentials of PTD and HE-PPD in
combination with their similar coloring abilities pointed to
these molecules as excellent examples of the class of
monocyclic aromatic amines that should be distinguishable
in our in vitro test system.
The various in vitro approaches already published have
been used with limited success for the detection of the
sensitizing potential of chemicals (Kimber et al, 2001; Ryan
et al, 2001). These studies, however, demonstrated that
exposure to sensitizers modulates the expression of some
DC activation markers in vitro. We thus decided to set up an
optimized in vitro test system for measuring the activation of
in vitro generated immature DC-like cells by chemicals
through quantitative analysis of DC activation markers. We
based our approach on immature DC generated by a short
5 d culture. DC obtained with similar protocols have been
shown to be functionally active in mixed leukocyte reactions
(Reutter and Jaeger, 1997; Ebner et al, 2001) or after
additional stimulation with TNF-a were shown to be able to
prime T cells following exposure to sensitizers (Guironnet
et al, 2000). A possible unspecific induction of activation
markers was limited by coating the bottom of the culture
wells with an agarose matrix in order to avoid direct contact
with the plastic material (Degwert et al, 1997; Aeby and
Bracher, 1999). DC differentiation state was monitored by
HLA-DR, CD14, and CD86 measurements (see Fig 1). The
influence of the apparent variations between donors used
as a source of DC progenitors observed by Reutter and
Jaeger (1997) and Pichowski et al (2000) was minimized by
the use of cell pools obtained from four different donors
(Aeby and Bracher, 1999).
Analysis of DC activation was performed using CD86 and
IL-1b as significant markers, since both were shown to be
upregulated by murine and human Langerhans’ cells during
the initiation of contact sensitization in the skin (Enk et al,
1993; Ozawa et al, 1996; Rambukkana et al, 1996; Katayama
et al, 1997; Kimber et al, 1998; Kermani et al, 2000; Mellman
and Steinman, 2001; Stoitzner et al, 2003). Moreover, CD86
and IL-1b are generally considered suitable markers for
developing an in vitro test system for contact sensitizers
and allow a widespread comparison with already published
data as far as in vitro activation of DC by contact sensitizers
is concerned (Aiba et al, 1997; Reutter and Jaeger, 1997;
Pichowski et al, 2000, 2001; Tuschl and Kovac, 2001; De
Smedt et al, 2002). Other specific markers of DC activa-
tion, such as tyrosine phosphorylation or CD83/CD208
Figure 5
Concentration- and vehicle-dependent differences in LLNA re-
sponse. Groups of mice (n¼ 5) received topical applications on the
dorsum of both ears of 25 mL of PTD () or HE-PPD (’) in the vehicle
acetone/aqua/olive oil (AAOO) in doses of 2.8%, 1.5%, and 0.5% for 3
consecutive days. Additionally, groups of mice received applications of
HE-PPD in DMSO in doses of 2.0%, 1.0%, and 0.5% (&) for the same
period. On day 5 following the initiation of the treatment all mice were
injected intravenously with radioactive thymidine and its respective
incorporation into the auricular lymph nodes was measured as
described. The arithmetic mean of the stimulation index and the
standard deviation relative to the concurrent vehicle-treated control is
shown for each concentration tested.
Figure 6
Percutaneous penetration rates of HE-PPD and PTD in different
vehicles. The surface of pig skin samples was incubated with 100mL
per cm2 of acetone/aqua/olive oil (AAOO) containing 0.6% PTD
() (n¼ 5) or 1.6% HE-PPD (’) (n¼6) for 30 min. Additionally,
skin samples (n¼ 6) were treated with 1.6% HE-PPD in DMSO (&) for
the same period. Remaining amounts of the test substances were
removed after 30 min by extensive washing using a shampoo. At the
points in time indicated the cumulative cutaneous absorption was
determined in the receptor fluid as described. The mean of the
respective amount absorbed and the standard deviation is shown for
each time point.
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modulation, were not included, since their expression after
exposure to contact sensitizers need a very short exposure
period (15 min, Becker et al, 2003) not compatible with our
test system, or have been described to be either weak (Aiba
et al, 2000; De Smedt et al, 2002), or yield very similar
information as provided by CD86 measurement (de Saint-Vis
et al, 1998).
In general, the modulation of the activation markers
through sensitizers was expected to be rather weak.
Reutter and Jaeger (1997) and Pichowski et al (2000)
observed a maximum of 2–3-fold increase in IL-1b gene
expression using semi-quantitative PCR measurements.
Such increases are barely detectable with semi-quantitative
PCR approaches and we decided to perform IL-1b gene
expression measurements with a quantitative methodology
and opted for real-time PCR using the LightCycler system.
To exclude unspecific signals due to experimental artifacts
that may lead to the overall unspecific upregulation of the
measured parameters, we wanted to include a down-
regulated DC maturation marker in our test battery.
Recently, the role of aquaporins that regulate the flow of
water during macropinocytosis in immature DC has been
analyzed (de Baey and Lanzavecchia, 2000). These authors
have shown that two members of the aquaporin family,
AQP3 and AQP7, are downregulated during DC activation.
A protocol for AQP3 mRNA measurement by real-time RT-
PCR was developed and this marker was included in our
test battery. Taken together, our strategy was to show that
exposure to a contact sensitizer induces modifications of
three functionally different markers, that is, DC switch from
a state with low costimulation capacity (CD86þ /), high
antigen uptake (AQP3þ ), and low migration signal (IL-1b)
to a state with a high costimulation (CD86þ þ ), low antigen
uptake (AQP3), and high migration signal (IL-1bþ ). That
test strategy is not limited to the markers used and additional
markers might be included to optimize the analysis of
contact sensitizers of different chemical classes. But the
three currently used markers represent a valid subset of the
known DC activation markers linked to contact sensitization,
are compatible with the current test protocol, and allow
comparison with already published data.
Next we analyzed the expression kinetics of the selected
endpoints (AQP3, CD86, and IL-1b) on in vitro generated DC
exposed to the model irritant SDS and the model sensitizer
TNBS (see Fig 3). The response of the test system differed
significantly after 30 h of exposure to the two substances:
DC were activated by the sensitizer but not by the irritant.
Longer exposure periods (e.g., 48 h) affected the cell viabi-
lity and were not analyzed. Exposure periods shorter than
11 h did not produce useful signals. Thirty-hour exposure
was thus chosen as the optimum exposure time for the
differential expression of the selected activation markers.
This exposure time is comparable with those published by
other groups who measured protein markers (Aiba et al,
1997; Degwert et al, 1997; Tuschl and Kovac, 2001). It is,
however, much longer than the exposure period (30 min)
used by Reutter and Jaeger (1997) or Pichowski et al (2000)
who measured IL-1b gene expression at the mRNA level.
This optimized test protocol was then applied for
comparing the dose response curves of PTD, HE-PPD
and TNBS (see Fig 4). The concentrations required to
induce similar effects on the selected activation markers
were approximately four to eight times higher for HE-PPD
than for PTD. We concluded that PTD is approximately four
to eight times more potent for inducing DC activation in vitro
than HE-PPD. The dose response curve of TNBS was in the
same range as those of the aromatic amines. In order to
check the relevance of these in vitro findings, PTD and
HE-PPD were evaluated in vivo in the murine LLNA.
The LLNA results obtained with PTD in AAOO were in line
with its comparatively potent biological activity in the DC
maturation assay. The EC3 of 0.31% indicates that topical
application of relatively low concentrations of PTD suffice to
induce an LLNA response above 3 indicating the induction
of a specific immune response (see Fig 5). Under the same
conditions, HE-PPD did not induce a positive response.
This lack of an LLNA response was unexpected since the
results of the in vitro DC activation assay did indicate a clear
activity of HE-PPD for all three markers tested, although it
was four to eight times less potent than PTD (see Fig 4).
Could differences in the bioavailability of PTD and HE-
PPD be responsible for their different ability to induce a
LLNA response? In vitro assessment of their skin penetra-
tion properties using the pig skin model revealed that the
bioavailability of PTD was approximately 200 times higher
than that of HE-PPD when applied in AAOO (see Fig 6).
Table I. Mean % of cumulative cutaneous absorptiona
Vehicle
Test substance
PTD HE-PPD
AAOO Commercial formulationb AAOO DMSO Commercial formulationc
Receptor fluid 4.1  1.2 0.28  0.12 0.022  0.008 0.118  0.01 0.017  0.005
Rinsing solution 100.8  3.9 97.3  11.1 105.9  4.2 97.4  2.6 84.9  8.2
Total balanced 107.7  4.5 97.8  11.0 107.0  4.1 98.4  2.6 85.0  8.1
aMean % of cumulative cutaneous absorption  SD is given.
bFormulation contains: water, cetearyl alcohol, glyceryl stearate SE, sodium laureth sulfate, glycol distearate, ammonia, lanolin alcohol, sodium lauryl
sulfate, isopropyl alcohol, sodium sulfite, ascorbic acid, benzoic acid. Experiment was terminated after 24 h.
cFormulation contains: water, cetearyl alcohol, 2-amino-4-hydroxyethylaminoanisole sulfate, sodium laureth sulfate, ammonia, sodium sulfite, benzoic
acid.
dValues given include amount found in the skin.
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When applied in DMSO, a vehicle known to increase dermal
bioavailability (Priborsky and Muhlbachova, 1990; Kim et al,
1999; Ryan et al, 2002), the penetrating properties of HE-
PPD were enhanced 5-fold. Besides the enhancement of
skin penetration, DMSO probably also affected the sensitiz-
ing potential of HE-PPD in vivo by additional mechanisms
such as the modulation of cytokines necessary for DC
maturation and/or induction of dermal irritation. These
effects that were reported for DMSO (Depraetere et al,
1995; Sjogren and Anderson 2000) and for other vehicles
(Lea et al, 1999; Warbrick et al, 1999; Wright et al, 2001,
reviewed in Basketter et al, 2001) possibly led to an
overestimation of the relative sensitizing potency of HE-
PPD in the corresponding LLNA performed in DMSO with
respect to an EC3 of 0.62%. Notwithstanding, the LLNA
response showed a concentration-dependent increase in
the stimulation index (see Fig 5) as expected from the
concentration-dependent biological activity of HE-PPD
observed in the in vitro DC activation assay (see Fig 4).
We concluded that in vitro assessment of DC activation
combined with skin penetration measurements allowed the
correct prediction of the sensitizing properties of the two
selected aromatic amines: The higher sensitizing potential
of PTD versus HE-PPD can be correctly predicted due to a
relatively strong induction of DC activation and a high skin
penetration capacity. The relatively lower sensitizing poten-
tial of HE-PPD can be correctly predicted since it was less
effective than PTD in inducing DC maturation and had much
lower skin penetrating properties using either AAOO or
DMSO as vehicles.
Interestingly, TNCB (trinitrochlorobenzene), a chemical
that forms the immunologically identical hapten as does
TNBS (Robinson, 1989), induced an EC3 of 0.26% in
dimethylformamide (Smith and Hotchkiss, 2001), which is in
the same order of magnitude as the EC3 values of 0.31%
for PTD and of 0.62% for HE-PPD. This finding also
supports the good predictivity of our in vitro test system
since TNBS, PTD, and HE-PPD induced comparable
activation of DC (see Fig 4).
Taken together, the quantitative evaluation of DC activa-
tion through upregulation of IL-1b and CD86 as well as
downregulation of AQP3 has provided a correct estimation
of the skin sensitizing potential of the tested chemicals
when bioavailability is not limited by dermal penetration. To
establish a robust prediction model more chemicals have to
be tested and corrective factors for in vitro metabolism and
in vitro protein binding have to be addressed. On the basis
of these future refinements the analysis of DC activation will
become a useful tool to screen new industrial chemicals
and cosmetic ingredients for their sensitizing potential
without increasing the number of animal experiments.
Materials and Methods
Animals Female CBA/ca01aHsd mice were obtained from Harlan
Winkelmann GmbH, Germany. A standard diet (1324 Altromin,
Germany) and tap water were offered ad libitum. Mice were 8–12 wk
old at the onset of the experiments.
Materials p-Toluylenediamine sulfate (PTD; CAS-no. 6369-59-1)
and hydroxyethyl-p-phenylenediamine sulfate (HE-PPD; CAS-no.
93841-25-9) of documented purity were purchased from Wella
production, Hu¨nfeld, Germany. 2,4,6-Trinitrobenzenesulfonic acid
(TNBS) (CAS-no. 2508-19-2) 5% (wt/vol) solution in water and
sodium lauryl sulfate (SDS) (CAS-no. 151-21-3) were purchased
from Sigma, Buchs, Switzerland. 3H-Methylthymidine (TRK 300, 25
Ci per mmol) from Amersham Pharmacia Biotech, Roosendaal, NL
was diluted to a working concentration of 80 mCi per mL. Trichlo-
roacetic acid (TCA) and olive oil (OO), highly refined, were pur-
chased from Sigma GmbH, Munich, Germany, phosphate-buffered
saline (PBS) was from BSL Bioservice, Planegg, Germany, and
acetone was purchased from Biesterfeld/Bender and Hobein,
Hamburg, Germany. Dimethylsulfoxide (DMSO) was from Fluka,
Munich, Germany.
Culture medium The culture medium was RPMI 1640 without
phenol red (Sigma, Buchs, Switzerland) supplemented with
10% fetal calf serum (Amimed, Allschwill, Switzerland), 2 mM
L-glutamine (Biochrom KG, Berlin, Germany), 800 U per mL of
rhGM-CSF (Leucomax, Essex Chemie AG, Luzern, Switzerland),
and 1000 U per mL of IL-4 (Strathmann Biotech GmbH, Hannover,
Germany) referred below as complete culture medium.
Puriﬁcation of human monocytes and generation of dendritic-
like cells Fresh buffy coats were obtained from Blutspendedienst
SRK Bern AG, Bern, Switzerland according to a written informed
consent agreement signed by the transfusion center and the
first author. An enriched monocytic cell fraction was isolated
by sequential density centrifugation on Ficoll-Paque PLUS and
Percoll (Amersham Pharmacia Biotech AB, Uppsala, Sweden) den-
sity gradients as described (Degwert et al, 1997). The enriched
monocytes were stored in liquid nitrogen. Monocyte-derived den-
dritic-like (DC-like) cells were generated by thawing and pooling
the enriched monocytes from four different donors and growing
them up to 5 d in complete culture medium at 371C, 5% CO2 in 12-
well-culture plates (Falcon Becton Dickinson, Franklin Lakes, New
Jersey) plating 1–2  106 cells in 2 mL per well. The wells were
pre-coated with 0.5 mL of a 2% agarose matrix (Agarose gel,
insect cell culture tested, Gibco, Basel, Switzerland) and equili-
brated with complete culture medium before use. Every second
day, half of the culture medium was replaced by fresh medium. The
CD1a, CD14, CD86, and HLA-DR phenotypes were regularly
monitored as markers of differentiation into DC-like cells. At day 4,
the DC-like cells were used for the in vitro sensitization test.
Flow cytometry analysis Cells were prepared for flow cytometry
analysis by washing 1–2  106 cells in PBS followed by a 15 min
incubation at 41C with the indicated fluorescein isothiocyanate
(FITC) or phycoerythrin (PE) labeled antibodies at concentrations
recommended by the manufacturer. The following antibodies
were used: anti-CD1a-FITC, clone HI149, anti-CD86-FITC, clone
2331(FUN-1) (BD Biosciences, Basel, Switzerland), anti-CD45-
FITC/anti-CD14-PE, clones IMMU19.2 and RMO52 and anti-HLA-
DR-FITC, clone B8.12.2 (Beckman Coulter, Zu¨rich, Switzerland).
Non-specific staining was determined using relevant isotypic
controls in parallel. Gates based on forward and side scatter
signals were set to exclude most T lymphocytes, dead cells, and
debris. Approximately 10,000 cells were analyzed during each
measurement. The flow cytometry was performed on a Coulter
EPICS XL (Beckman Coulter) analyzer in the FL1 channel at 525 nm
for FITC labeled and in the FL2 channel at 575 nm for PE labeled
antibodies. Cell viability was determined by measuring the
percentage of cells positive in the FL1 channel (living cells) after
20 min incubation with 50 ng per mL fluorescein diacetate (FDA,
Sigma, Buchs, Switzerland). The data analysis was performed with
the SYSTEM II, v.3.0 software (Beckman Coulter). Graphs were
prepared for publication using WinMDI Version 2.8 (Joseph Trotter,
http://facs.scripps.edu/).
In vitro sensitization test protocol At day 4, 100 mL of test items
or of negative control (deionized water) were added to 2 mL wells
containing 1–2  106 DC-like cells. After 6 h, half of the medium
was replaced by fresh complete medium. At the indicated time
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points, cells were harvested for RT-PCR and/or flow cytometry
analysis.
RNA extraction and cDNA synthesis Total RNA was isolated
from each 2 mL well containing 1–2  106 DC-like cells using
RNAzol B (Ams biotechnology Europe Ltd, Bioggo, Switzerland)
according to the manufacturer’s instructions. RNA was pelleted by
centrifugation at 10,000  g for 15 min, washed with 75% ethanol
and suspended in 50 mL of TE buffer at pH 8.0 (Amresco,
BioConcept, Allschwil, Switzerland). The RNA concentration was
determined by measurement of the OD260 and adjusted to 50 mg
per mL. Four hundred and fifty nanograms of purified total RNA (9
mL) was used for cDNA synthesis using the ThermoScript RT-PCR
system (Invitrogen AG, Basel, Switzerland) using the provided
random hexamers (50 ng per reaction) according to the user
manual instructions.
PCR analysis of gene expression with the LightCycler
system Quantitative PCR amplification of the 28S ribosomal
RNA (28S rRNA), IL-1b, and aquaporin 3 (AQP3) cDNAs was
performed in glass capillaries with the LightCycler instrument
(Roche Diagnostics AG, Rotkreuz, Switzerland). The PCR reactions
were set up using the LightCycler-FastStart DNA Master SYBR
Green I kit (Roche Diagnostics GmbH, Mannheim, Germany)
according to the manufacturer’s instructions. Briefly, 2 mL of a
1/10 diluted cDNA solution (28S rRNA: 1/50 dilution), the desired
amount of MgCl2 stock solution, 20 pmol each of the specific
primers (Microsynth GmbH, Balgach, Switzerland) according to
Table II and PCR grade water were added to the master mix up to a
final volume of 20 mL. The experimental protocol included an initial
denaturation step at 951C for 10 min followed by 40 amplification
cycles (denaturation: 951C for 15 s; annealing: primer specific
temperature according to Table II for 5 s; elongation: 721C for 1s
per 25 bp of amplicon length). Ramp rates were set to 201C per s.
SYBR Green I fluorescence was measured at the end of each
elongation cycle. The level of primer–dimer formation and/or
unspecific amplification products was monitored by melting curve
analysis. The respective gene products were quantified by direct
comparison with standards amplified in parallel reactions. As
standards, we used serial dilutions (1/10–1/1000) of a batch of
cDNA obtained from stimulated DC-like cells. The same batch of
cDNA was used as standard for the negative control and all treated
samples run in parallel. The same batch of cDNA, however, could
not be used for all experiments due to amount and stability issues,
and the results are therefore expressed as percentage of the
respective negative control. All calculation steps necessary to
generate a standard curve were performed with the LightCycler
Software 3.5 using the second derivative maximum method. The
generated standard curve was used to calculate the relative
concentrations of target gene products in the unknown samples
and in the negative control. In each sample, the gene expression
level was further normalized to its 28S rRNA content by computing
the ratio relative amount of gene cDNA/relative amount of 28S
rRNA cDNA. The results are then expressed as percentage of the
respective negative control.
Dermal absorption The experimental setup as well as the
preparation and storage of the male porcine skin used in these
experiments have been published in detail (Bracher et al, 1987;
Noser et al, 1988; Beck et al, 1993). The cutaneous absorption of
HE-PPD (in DMSO and acetone/aqua/olive oil; 2:2:1 (¼AAOO))
and PTD in AAOO was investigated in vitro, using split thickness
pig skin samples from back and flanks (‘‘Schweizer Edelschwein’’,
1 mm thick; stratum corneum, stratum germinativum and part of
the dermis containing blood vessels, stored at 201C until use).
The skin preparations were punched and fixed into the permeation
chambers (Frantz cell type, CVO Glassware Co, Berkeley, California;
0.785 cm2 surface) at the beginning of the experiment, kept in an
incubator and continuously rinsed from underneath (dermal side)
with physiological receptor fluid (flow 2.5 mL per h) at a tem-
perature of 321C and a constant relative humidity during the whole
experiment of 72 h. Prior to the experiment the skin integrity was
checked with tritiated water by scintillation counting of 1 h frac-
tions over 4 h. Six skin samples were covered with 78 mL partially
14C-labelled HE-PPD in AAOO and DMSO, respectively, containing
1.6% of HE-PPD (¼ 1.58 mg HE-PPD per cm2). Five skin samples
were covered with 78 mL of AAOO containing 0.6% PTD (¼ 0.59
mg PTD per cm2), and one skin sample was covered with the
vehicle only as a negative control. The solution was removed after
30 min, followed by extensive washing with deionized water and a
commercially available shampoo. The receptor fluid was sampled
after 16, 24, 40, 48, 64, and 72 h.
Analysis of samples from dermal absorption Receptor fluid:
The partially 14C-labelled HE-PPD was analyzed by liquid scintilla-
tion counting (Packard Tricarb 2250CA, Downers Grove, Illinois)
with a dual mode 3H/14C program. For PTD 10 mL of the recep-
tor fluid was reacted with 2.5 mL buffer (25 mM K2HPO4  3H2O;
Merck 1.05099.0250, Darmstadt, Germany; p.a.; pH  8.3 adjusted
with H3PO4; Merck 573, Darmstadt, Germany; p.a.) and 1 mL of
a dansyl-chloride solution (Sigma D-2625, St Louis, Missouri;
approximately 95%; to 1.5 mg per mL acetonitrile; Biosolve,
Valkenswaard, The Netherlands; HPLC grade) during 2 h at 501C,
and then butanol was extracted, evaporated to dryness, redis-
solved in the mobile phase, and an aliquot was taken for HPLC.
Control injections were prepared with permeation fluid from the
control skin using the same derivatization and extraction proce-
dures. Rinsing solution: For HE-PPD an aliquot of each washing
solution was analyzed as described above. For PTD an aliquot was
diluted in deionized water and reacted in the physiological solution
buffer and dansyl-chloride solution, thereafter processed as
described above. An HPLC system (Waters 996, Milford, Massa-
chusetts) combined with a fluorescence detector (Gynkotek, RF
1002, Germering, Germany) and controlled by Millenium software
Table II. Primers, amplicons’ sizes and PCR conditions
mRNA target Primers (50–30)
Annealing
temperature
(1C)
MgCl2 ﬁnal
concentration
(mM)
Amplicon
size
(bp)
GenBank
accession
no.
28S ribosomal RNA CGGTACACCTGTCAAACGGTAAC 65 4 507 M11167
TTAGAGGCGTTCAGTCATAATCCC
Interleukin-1b AAACAGATGAAGTGCTCCTTCCAGG 60 4 391 X02532
TGGAGAACACCACTTGTTGCTCCA
Aquaporin 3 TCTGGCACTTTGCCGACAAC 58 3 472 AB001325
GGCCAGCTTCACATTCTCTTC
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was used for analyses at an excitation of 340 nm and an emission
of 525 nm under the following conditions: column: 4 micron C18
Nova-Pak from Waters, 3.9  150 mm, with an appropriate pre-
column (Waters); mobile phase: 60% methanol (Biosolve; HPLC-
grade) and 0.5% acetic acid (Merck 6325, Darmstadt, Germany;
p.a.); flow: 0.8 mL per min.
Local lymph node assay Murine LLNA were conducted as
described previously (Kimber and Basketter, 1992). Briefly, groups
of mice (n¼ 5) were exposed topically on the dorsum of both ears
to 25 mL of various concentrations of the test items, or to the same
volume of the respective vehicle alone, daily for 3 consecutive
days. To achieve maximum solubility, PTD and HE-PPD were
dissolved in deionized water and a pH between 5 and 7.5 was
adjusted with NaOH. The respective aqueous solutions were mixed
with acetone 1:1 (vol/vol) to receive aqua/acetone (AA) and finally
mixed 4:1 (vol/vol) with OO and will be referred to as AAOO.
Additionally, DMSO served as vehicle. Five days following the
initiation of the treatment, all mice were injected intravenously
via the tail vein with 250 mL of PBS containing 20 mCi 3H
methylthymidine. Five hours later mice were euthanized and
draining auricular lymph nodes were excised and pooled for each
animal. Single cell suspensions were prepared by mechanical
desegregation through a 200-mesh size polyamide gauze. Cells
were washed twice with PBS and precipitated in 5% TCA at 41C
overnight. Pellets were then resuspended in 1 mL of 5% TCA and
transferred into scintillation vials. Incorporation of 3H-methylthy-
midine was measured by b-scintillation counting as disintegrations
per minute per node for each animal. In each case a stimulation
index relative to the concurrent vehicle treated control was derived.
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